[1] 范建高. 中国非酒精性脂肪性肝病的流行病学.中国医师进修杂志（综合版）,2010,33（1）:4-6.
[2] De alwis NM,Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol,2008,48 （Suppl 1）:S104-112.
[3] 范建高,钟妍. 非酒精性脂肪性肝病患者代谢紊乱发病率增高.胃肠病学,2007,12（12）:717-719.
[4] Adams LA,Lymp JF,St sauver J,et al. The natural history of nonalcoholic fatty liver disease:a population-based cohort study. Gastroenterology,2005,129（1）:113-121.
[5] 范建高,李锋,蔡晓波,等. 1995至2002年上海宝钢职工队列人群脂肪肝患病率变化. 肝脏2006,11（3）:154-157.
[6] Oza N,Eguchi Y,Mizuta T,et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol,2009,44（12）:1203-1208.
[7] St george A,Bauman A,Johnston A,et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology,2009,50（1）:68-76.
[8] Nar A,Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol,2009,46（2）:113-118.
[9] Vilar gomez E,Rodriguez de miranda A,Gra oramas B,et al. Clinical trial:a nutritional supplement Viusid,in combination with diet and exercise,in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther,2009,30（10）:999-1009.
[10] Promrat K,Kleiner DE,Niemeier HM,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology,2010,51（1）:121-129.
[11] Chang Y,Ryu S,Sung E,et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut,2009,58（10）:1419-1425.
[12] Sanyal AJ,Chalasani N,Kowdley KV,et al. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362（18）:1675-1685.
[13] Abdelmalek MF,Angulo P,Jorgensen RA,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis:results of a pilot study. Am J Gastroenterol,2001,96（9）:2711-2717.
[14] Abdelmalek MF,Sanderson SO,Angulo P,et al. Betaine for nonalcoholic fatty liver disease:results of a randomized placebo-controlled trial. Hepatology,2009,50（6）:1818-1826.
[15] Gómez-domínguez E,Gisbert JP,moreno-monteagudo JA,et al. A pilot study of atorvastatin treatment in dyslipemid,non-alcoholic fatty liver patients. Aliment Pharmacol Ther,2006,23（11）:1643-1647.
[16] Nelson A,Torres DM,Morgan AE,et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis:A randomized placebo-controlled trial. J Clin Gastroenterol,2009,43（10）: 990-994.
[17] Abel T,Fehér J,Dinya E,et al. Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease. Orv Hetil,2009,150（21）:989-993.
[18] Belfort R,Harrison SA,Brown K,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med,2006,355（22）:2297-2307.
[19] Gastaldelli A,Harrison SA,Belfort-aguilar R,et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology,2009,50（4）:1087-1093.
[20] Ratziu V,Charlotte F,Bernhardt C,et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis:results of the fatty liver improvement by rosiglitazone therapy（FLIRT 2）extension trial. Hepatology,2010,51（2）:445-453.
[21] Bugianesi E,Gentilcore E,Manini R,et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol,2005,100（5）:1082-1090.
[22] Omer Z,Cetinkalp S,Akyildiz M,et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol,2010,22（1）:18-23.
[23] Nagao K,Inoue N,Inafuku M,et al. Mukitake mushroom （Panellus serotinus）alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice. Nutr Biochem,2010,21（5）:418-423.
[24] Rosselli MS,Burgueo AL,Carabelli J,et al. Losartan reduces liver expression of plasminogen activator inhibitor-1（PAI-1） in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis,2009,206（1）:119-126.
[25] Aragno M,Tomasinelli CE,Vercellinatto I,et al. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med,2009,47（7）:1067-1074. |
